TABLE 1.
Patient data
| Patients (n=107) % | Stage II-III (n=61) % | Stage IV (n=46) % | p | |
|---|---|---|---|---|
| Gender | ||||
| Female | 51.4 | 39.3 | 67.4 | 0.004 |
| Male | 48.6 | 60.7 | 32.6 | |
| Age (years) Mean±SD | 60.8±12.8 | 57.5±12.8 | 64.5±12.0 | 0.008 |
| Comorbidity | ||||
| HT | 29.0 | 24.6 | 34.8 | 0.250 |
| DM | 8.4 | 8.2 | 8.7 | 0.927 |
| CIHD | 5.6 | 6.6 | 4.3 | 0.619 |
| CPOD | 3.7 | 3.3 | 4.3 | 0.774 |
| Smoking | 50.5 | 41.0 | 63.0 | 0.024 |
| Alcohol consumption | 3.7 | 0.0 | 8.7 | 0.019 |
| Symptom | ||||
| Dysphagia | 89.7 | 91.8 | 87.0 | 0.525 |
| Abdominal pain | 23.4 | 23.0 | 23.9 | 0.907 |
| Weight loss | 29.0 | 23.0 | 37.0 | 0.114 |
| Presence of obstruction | 49.5 | 36.1 | 67.4 | 0.001 |
| ECOG PS | ||||
| 0–2 | 93.5 | 96.7 | 89.1 | 0.336 |
| 3–4 | 6.5 | 3.3 | 10.9 | |
| Grade | ||||
| I-II | 82.2 | 88.5 | 73.9 | 0.051 |
| III | 17.8 | 11.5 | 26.1 | |
| Clinical-stage | ||||
| II | 26.2 | 45.9 | ||
| III | 30.8 | 54.1 | ||
| IV | 43.0 | 100.0 | ||
| Primary tumor localization | ||||
| Upper 1/3 | 12.1 | 9.8 | 15.2 | 0.120 |
| Middle 1/3 | 57.0 | 65.6 | 45.7 | |
| Lower 1/3 | 30.8 | 24.6 | 39.1 | |
| Treatments | ||||
| Definitive CRT | 27.1 | |||
| CRT followed by surgery | 27.1 | |||
| Surgery alone | 4.9 | |||
| Neoadjuvant CRT regimen | ||||
| CP | 48.3 | 48.3 | ||
| CF | 51.7 | 51.7 | ||
| Definitive CRT regimen | ||||
| CP | 44.8 | 44.8 | ||
| CF | 55.2 | 55.2 | ||
| Surgery | 35.5 | 52.5 | 13.0 | <0.001 |
| Recurrence | ||||
| No | 55.7 | |||
| Local | 8.2 | |||
| Systemic | 36.1 | |||
| The site of metastasis at diagnosis | ||||
| Distant LN | 41.3 | 41.3 | ||
| Liver | 26.1 | 26.1 | ||
| Lung | 30.4 | 30.4 | ||
| Bone | 10.9 | 10.9 | ||
| Peritoneum | 6.5 | 6.5 | ||
| First-line treatment in metastatic setting | ||||
| CT | 53.4 | 48.1 | 56.5 | 0.489 |
| BSC | 46.6 | 51.9 | 43.5 | |
| First-line CT regimen | ||||
| CF | 66.7 | 46.2 | 76.9 | 0.077 |
| CP | 33.3 | 53.8 | 23.1 | |
| Final status | ||||
| Dead | 60.7 | 41.0 | 87.0 | <0.001 |
| Alive | 39.3 | 59.0 | 13.0 |
BSC: Best supportive care; CF: Cisplatin-5-florourasil; CIHD: Chronic ischemic heart disease; COPD: Chronic obstructive lung disease; CP: Carboplatin-paclitaxel; CRT: Chemoradiation; CT: Chemotherapy; ECOG PS: Eastern Cooperative Oncology Group Performance Status; DM: Diabetes mellitus; HT: Hypertension; Max.: Maximum; Min.: Minimum; LN: Lymph node; SD: Standard deviation.